MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$50,959K
Net Income
-$23,585K
Net Profit Margin
-46.28%
Unit: Thousand (K) dollars
Revenue Breakdown
Zusduri
Jelmyto
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Revenue
50,959
37,837
27,482
24,215
Cost of revenue
4,139
3,289
3,278
3,550
Gross profit
46,820
34,548
24,204
20,665
Research and development expenses
15,597
14,314
14,008
18,914
Selling, general and administrative expenses
51,486
39,349
37,582
43,199
Operating loss
-20,263
-19,115
-27,386
-41,448
Financing on prepaid forward obligation
4,506
4,655
4,621
4,644
Interest expense on long-term debt
4,185
3,772
3,373
4,132
Interest and other income, net
608
903
979
1,299
Loss before income taxes
-28,346
-26,639
-34,401
-48,925
Income tax benefit (expense)
-4,772
-275
-1,054
1,015
Net loss
-23,574
-26,364
-33,347
-49,940
Unrealized loss on investments
-11
-4
17
-8
Comprehensive loss
-23,585
-26,368
-33,330
-49,948
Basic EPS
-0.47
-0.535
-0.69
-1.05
Basic Average Shares
50,182,758
49,245,071
48,057,386
47,739,816
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$23,585K
(46.26%↑ Y/Y)
Net loss
-$23,574K
(46.23%↑ Y/Y)
Unrealized loss on
investments
-$11K
(73.81%↑ Y/Y)
Income tax benefit
(expense)
-$4,772K
(-1317.35%↓ Y/Y)
Zusduri
$29,246K
Jelmyto
$21,713K
Loss before income
taxes
-$28,346K
(34.76%↑ Y/Y)
Interest and other
income, net
$608K
(-71.24%↓ Y/Y)
Revenue
$50,959K
(151.60%↑ Y/Y)
Operating loss
-$20,263K
(45.11%↑ Y/Y)
Financing on prepaid
forward obligation
$4,506K
(-1.68%↓ Y/Y)
Interest expense on
long-term debt
$4,185K
(2.88%↑ Y/Y)
Gross profit
$46,820K
(161.21%↑ Y/Y)
Cost of revenue
$4,139K
(77.64%↑ Y/Y)
Selling, general and
administrative expenses
$51,486K
(47.24%↑ Y/Y)
Research and development
expenses
$15,597K
(-21.51%↓ Y/Y)
Buy us a coffee
UroGen Pharma Ltd. (URGN)
UroGen Pharma Ltd. (URGN)